Publicacións en colaboración con investigadores/as de Universitat d'Alacant (21)

2023

  1. Immune thrombotic thrombocytopenic purpura in older patients: Results from the Spanish TTP Registry (REPTT)

    British Journal of Haematology, Vol. 203, Núm. 5, pp. 860-871

  2. La expedición Balmis en el Suplemento a la Gazeta de Madrid (14 de octubre de 1806), difusión hispana

    Revista Espanola de Salud Publica, Vol. 97

2022

  1. Cardiac protection induced by urocortin-2 enables the regulation of apoptosis and fibrosis after ischemia and reperfusion involving miR-29a modulation

    Molecular Therapy - Nucleic Acids, Vol. 27, pp. 838-853

2021

  1. Gender-based differences by age range in patients hospitalized with covid-19: A spanish observational cohort study

    Journal of Clinical Medicine, Vol. 10, Núm. 5, pp. 1-21

  2. Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: the BIBABRAX study

    Cancer Chemotherapy and Pharmacology, Vol. 87, Núm. 4, pp. 543-553

  3. Predicting critical illness on initial diagnosis of COVID-19 based on easily obtained clinical variables: development and validation of the PRIORITY model

    Clinical Microbiology and Infection, Vol. 27, Núm. 12, pp. 1838-1844

2020

  1. ASTRIS, a large real-world study to evaluate the efficacy of osimertinib in epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer patients: Clinical characteristics and genotyping methods in a Spanish cohort

    Revista Espanola de Patologia, Vol. 53, Núm. 3, pp. 140-148

  2. Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL)

    Lung Cancer, Vol. 150, pp. 62-69

  3. Spanish guidelines for diagnosis, management, treatment, and prevention of dress syndrome

    Journal of Investigational Allergology and Clinical Immunology, Vol. 30, Núm. 4, pp. 229-253

2019

  1. DBP rs16846876 and rs12512631 polymorphisms are associated with progression to AIDS naïve HIV-infected patients: A retrospective study

    Journal of Biomedical Science, Vol. 26, Núm. 1

2018

  1. Epidemiología y prevención de los problemas de salud mental

    Manual de epidemiología y salud pública: para grados en ciencias de la salud (Editorial Médica Panamericana), pp. 241-244

2017

  1. Timed Up and Go Test Performance as an Indicator of Fall History in Institutionalized Elderly

    Topics in Geriatric Rehabilitation, Vol. 33, Núm. 4, pp. 273-279

2016

  1. Relationship between damage clustering and mortality in systemic lupus erythematosus in early and late stages of the disease: Cluster analyses in a large cohort from the Spanish Society of Rheumatology Lupus Registry

    Rheumatology (United Kingdom), Vol. 55, Núm. 7, pp. 1243-1250

2015

  1. A deletion at adamts9-magi1 locus is associated with psoriatic arthritis risk

    Annals of the Rheumatic Diseases, Vol. 74, Núm. 10, pp. 1875-1881

  2. Epirubicin plus cyclophosphamide followed by docetaxel versus epirubicin plus docetaxel followed by capecitabine as adjuvant therapy for node-positive early breast cancer: Results from the GEICAM/2003-10 study

    Journal of Clinical Oncology, Vol. 33, Núm. 32, pp. 3788-3795

2014

  1. Importance of exercise in the control of metabolic and inflammatory parameters at the moment of onset in type 1 diabetic subjects

    Experimental and Clinical Endocrinology and Diabetes, Vol. 122, Núm. 6, pp. 334-340

  2. Response to circulatory death determination in uncontrolled organ donors: A panel viewpoint

    Annals of Emergency Medicine

2007

  1. Control of diabetes and cardiovascular risk factors in patients with type 2 diabetes in primary care. The gap between guidelines and reality in Spain

    International Journal of Clinical Practice, Vol. 61, Núm. 6, pp. 909-915

  2. Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial

    Lancet Oncology, Vol. 8, Núm. 3, pp. 219-225

2006

  1. Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): Impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen

    Annals of Oncology, Vol. 17, Núm. 8, pp. 1205-1212